These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

156 related items for PubMed ID: 4369487

  • 1. [Antibody response in subjects vaccinated with a recall dose of the Sabin or Salk type vaccine].
    Squeri L, Calisto ML, Sindoni L, Mattace-Raso G.
    Ann Sclavo; 1973; 15(6):569-80. PubMed ID: 4369487
    [No Abstract] [Full Text] [Related]

  • 2. Evaluation of immunogenicity and protective properties of inactivated poliovirus vaccines: a new surrogate method for predicting vaccine efficacy.
    Dragunsky EM, Ivanov AP, Wells VR, Ivshina AV, Rezapkin GV, Abe S, Potapova SG, Enterline JC, Hashizume S, Chumakov KM.
    J Infect Dis; 2004 Oct 15; 190(8):1404-12. PubMed ID: 15378432
    [Abstract] [Full Text] [Related]

  • 3. Effect of tonsillectomy and adenoidectomy on nasopharyngeal antibody response to poliovirus.
    Ogra PL.
    N Engl J Med; 1971 Jan 14; 284(2):59-64. PubMed ID: 4321186
    [No Abstract] [Full Text] [Related]

  • 4. [Neutralizing antibodies in the sera of persons vaccinated with intradermal poliovirus vaccine].
    Jarzabek Z, Kańtoch M.
    Przegl Epidemiol; 1984 Jan 14; 38(3):323-6. PubMed ID: 6098935
    [No Abstract] [Full Text] [Related]

  • 5. CpG oligodeoxynucleotides are a potent adjuvant for an inactivated polio vaccine produced from Sabin strains of poliovirus.
    Yang C, Shi H, Zhou J, Liang Y, Xu H.
    Vaccine; 2009 Nov 05; 27(47):6558-63. PubMed ID: 19729087
    [Abstract] [Full Text] [Related]

  • 6. Prevalence of poliovirus neutralizing antibodies. A seroepidemiologic survey of vaccinated and unvaccinated women of fertile age.
    Moschen ME, Farisano G, Bonello C, Benussi G, Barbone F, Gasparini V, Trivello R.
    Boll Ist Sieroter Milan; 1987 Nov 05; 66(2):97-100. PubMed ID: 2822063
    [Abstract] [Full Text] [Related]

  • 7. Neutralizing capacity of poliovirus type 3 antibodies tested against 5 different intratypic variants of poliovirus type 3. A comparative study in children immunized with live, inactivated, or both types of poliovirus vaccines.
    Böttiger M.
    Arch Gesamte Virusforsch; 1971 Nov 05; 35(2):251-5. PubMed ID: 4332939
    [No Abstract] [Full Text] [Related]

  • 8. Rapid and accurate identification of poliovirus strains used for vaccine production.
    Nijst OE, Mouthaan JJ, Mekkes DR, Jusic E, van der Avoort HG, Metz B.
    J Virol Methods; 2013 Apr 05; 189(1):189-95. PubMed ID: 23434540
    [Abstract] [Full Text] [Related]

  • 9. Poliomyelitis vaccination in Thailand. I. A pilot study of the administration of live poliomyelitis vaccine.
    Sangkawibha N, Tuchinda P, Sakuntanaga P, Sunthornsaratul A, Kunasol P, Bukkavesa S, Ochasanonda P.
    Southeast Asian J Trop Med Public Health; 1974 Jun 05; 5(2):171-8. PubMed ID: 4370270
    [No Abstract] [Full Text] [Related]

  • 10. [Prospects in the field of the antipolio vaccination (author's transl)].
    Focà A.
    Ann Sclavo; 1980 Jun 05; 22(1):22-6. PubMed ID: 7018412
    [Abstract] [Full Text] [Related]

  • 11. Poliomyelitis prevention: enhanced-potency inactivated poliomyelitis vaccine--supplementary statement.
    Centers for Disease Control (CDC).
    MMWR Morb Mortal Wkly Rep; 1987 Dec 11; 36(48):795-8. PubMed ID: 3119980
    [No Abstract] [Full Text] [Related]

  • 12. A note on single- and two-dose immunogenicity tests of inactive virus vaccine in chicks.
    Slonim D, Drevo M.
    J Hyg Epidemiol Microbiol Immunol; 1976 Dec 11; 21(3):368-70. PubMed ID: 1033226
    [Abstract] [Full Text] [Related]

  • 13. Medicine and the media: polio still paralyses (Albert Sabin, Jonas Salk).
    Dixon B.
    Br J Hosp Med; 1977 Dec 11; 18(6):595. PubMed ID: 342023
    [No Abstract] [Full Text] [Related]

  • 14. Antipolio prophylaxis of immunocompromised children during a nationwide oral poliovaccine campaign.
    Stenvik M, Hovi L, Siimes MA, Roivainen M, Hovi T.
    Pediatr Infect Dis J; 1987 Dec 11; 6(12):1106-10. PubMed ID: 2829105
    [Abstract] [Full Text] [Related]

  • 15. Local antibody response to experimental poliovirus infection in the central nervous system of rhesus monkeys.
    Ogra PL, Ogra SS, al-Nakeeb S, Coppola PR.
    Infect Immun; 1973 Dec 11; 8(6):931-7. PubMed ID: 4361727
    [Abstract] [Full Text] [Related]

  • 16. Progress with inactivated poliovirus vaccines derived from the Sabin strains.
    Doi Y, Abe S, Yamamoto H, Horie H, Ohyama H, Satoh K, Tano Y, Ota Y, Miyazawa M, Wakabayashi K, Hashizume S.
    Dev Biol (Basel); 2001 Dec 11; 105():163-9. PubMed ID: 11763324
    [Abstract] [Full Text] [Related]

  • 17. Correlation between vaccine coverage against polio and circulation and genetic evolution of the poliovirus strains isolated in Romania in the framework of the global polio eradication strategy.
    Băicuş A, Persu A, Popescu M, Penciu A, Stavri S, Soare A, Grecu N, Szmal C, Oprişan G.
    Roum Arch Microbiol Immunol; 2009 Dec 11; 68(3):145-50. PubMed ID: 20361534
    [Abstract] [Full Text] [Related]

  • 18. Clinical development of a novel inactivated poliomyelitis vaccine based on attenuated Sabin poliovirus strains.
    Verdijk P, Rots NY, Bakker WA.
    Expert Rev Vaccines; 2011 May 11; 10(5):635-44. PubMed ID: 21604984
    [Abstract] [Full Text] [Related]

  • 19. Inactivated polio vaccine development for technology transfer using attenuated Sabin poliovirus strains to shift from Salk-IPV to Sabin-IPV.
    Bakker WA, Thomassen YE, van't Oever AG, Westdijk J, van Oijen MG, Sundermann LC, van't Veld P, Sleeman E, van Nimwegen FW, Hamidi A, Kersten GF, van den Heuvel N, Hendriks JT, van der Pol LA.
    Vaccine; 2011 Sep 22; 29(41):7188-96. PubMed ID: 21651934
    [Abstract] [Full Text] [Related]

  • 20. Reassessment of the place of inactivated poliomyelitis vaccine in national immunization programmes.
    Assaad F.
    Dev Biol Stand; 1981 Sep 22; 47():275-82. PubMed ID: 6262152
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.